Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework
- 1Department of Rehabilitation, The People's Hospital Medical Group of Xiangzhou
- 2Department of Intensive Care Unit, The People's Hospital Medical Group of Xiangzhou
Abstract
Blood pressure (BP) lowering is a key component of acute intracerebral haemorrhage (ICH) care. Its clinical benefit may depend on how early an appropriate BP range is reached, how steadily it is maintained, and how well the patient tolerates the reduction. We propose a Time–Trajectory–Phenotype framework to examine these dimensions together. Our central hypothesis is that early attainment and stable maintenance of an appropriate BP range may offer greater net benefit than delayed or fluctuating control when further haematoma expansion remains preventable and BP reduction is tolerated. Time encompasses treatment initiation and target attainment. Trajectory captures reduction magnitude and rate, subsequent variability, and sustained exposure within and outside the intended range. Phenotype distinguishes baseline expansion risk from cerebral and systemic tolerance of BP reduction. Randomised trials, serial imaging, and achieved-exposure analyses provide the clinical rationale for examining these dimensions together. The first three hours provide a clinically motivated focus for investigating a therapeutic opportunity that changes over time and varies between patients. Clinically, the framework supports early, sustained guideline-based control and avoidance of excessive reduction within coordinated ICH care. BP variability and time-in-target range are proposed as candidate metrics for prospective comparisons of treatment delivery. These studies should test whether faster target attainment and more stable control improve functional outcomes and safety, and whether treatment effects vary across patient phenotypes.
Related
- Predominantly mild thrombocytopenia, haematoma expansion and clinical outcomes in intracerebral haemorrhage
- C1qc Mediates Blood–Brain Barrier Disruption in a Mouse Model of Intracerebral Haemorrhage Through Microglia‐Derived Migrasomes
- Vagus Nerve Stimulation in Intracerebral and Subarachnoid Haemorrhage: A Systematic Review, Narrative Synthesis and Exploratory Meta-Analysis
- Predictive factors of hospital case-fatality in patients with spontaneous intracerebral haemorrhage.
- Postpartum risk and prognosis of pregnancy-associated intracerebral haemorrhage: a nationwide cohort-crossover study
BibTeX
@article{xia2026blood,
title = {{Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework}},
author = {Xin Ping Xia and Yu Zhang and Ling Zhao},
journal = {Frontiers in Neurology},
year = {2026},
month = oct,
doi = {10.3389/fneur.2026.1900479},
url = {https://www.frontiersin.org/articles/10.3389/fneur.2026.1900479/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Blood pressure management in acute intracerebral haemorrhage: a Time–Trajectory–Phenotype framework
AU - Xin Ping Xia
AU - Yu Zhang
AU - Ling Zhao
PY - 2026
DA - 2026/10/29
JO - Frontiers in Neurology
DO - 10.3389/fneur.2026.1900479
UR - https://www.frontiersin.org/articles/10.3389/fneur.2026.1900479/full
AB - Blood pressure (BP) lowering is a key component of acute intracerebral haemorrhage (ICH) care. Its clinical benefit may depend on how early an appropriate BP range is reached, how steadily it is maintained, and how well the patient tolerates the reduction. We propose a Time–Trajectory–Phenotype framework to examine these dimensions together. Our central hypothesis is that early attainment and stable maintenance of an appropriate BP range may offer greater net benefit than delayed or fluctuating control when further haematoma expansion remains preventable and BP reduction is tolerated. Time encompasses treatment initiation and target attainment. Trajectory captures reduction magnitude and rate, subsequent variability, and sustained exposure within and outside the intended range. Phenotype distinguishes baseline expansion risk from cerebral and systemic tolerance of BP reduction. Randomised trials, serial imaging, and achieved-exposure analyses provide the clinical rationale for examining these dimensions together. The first three hours provide a clinically motivated focus for investigating a therapeutic opportunity that changes over time and varies between patients. Clinically, the framework supports early, sustained guideline-based control and avoidance of excessive reduction within coordinated ICH care. BP variability and time-in-target range are proposed as candidate metrics for prospective comparisons of treatment delivery. These studies should test whether faster target attainment and more stable control improve functional outcomes and safety, and whether treatment effects vary across patient phenotypes.
SN - 1664-2295
ER -